ASCO News In Brief: IDEC Pharmaceuticals IDEC-C2B8
Executive Summary
IDEC Pharmaceuticals IDEC-C2B8: Overall response rate of 47.9% reported in preliminary results of Phase III pivotal trial of single-agent antibody treatment for patients with relapsed low-grade or follicular non-Hodgkin's lymphoma. Fifty of 166 evaluable patients have been analyzed and full results should be available in December 1996, the company said. The tumor marker gene, bcl-2, reverted from positive to negative in the peripheral blood of 12 of 16 patients and in the bone marrow of six of 12 patients evaluated. IDEC is developing IDEC-C2B8 in collaboration with Genentech, Roche and Zenyaku Kogyo of Japan...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth